ABSTRACT
INTRODUCTION
The role of the circadian rhythm in human life has been well known for a long time. The notion of the circadian rhythm introduced by Moreover, melatonin demonstrated antioxidant functions, which were laid into the foundation of its use in neurodegenerative diseases, e.g., Parkinson and Alzheimer's diseases [2] . Several experimental and clinical studies have revealed new melatonin properties such as oncostatic and immune-modulating effects, the capability to improve mood and to decrease anxiety, to affect the cardiovascular system and GIT, as well as the role of melatonin in reproductive functions and metabolism and body mass regulation [3] .
The analgesic capabilities of melatonin have always attracted much interest. Given that the contemporary therapy of chronic pain syndrome is far from perfect, constant search is required for new molecules with analgesic capabilities as well as the research into the existing substances used in the treatment of other conditions. The decisive factor is the combination of high efficacy and good safety profile of a drug [4] . Melatonin demonstrated efficacy and safety in nociceptive and neuropathic pain in several studies on animal models and clinical trials.
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MELATONIN IN EXPERIMENTAL RESEARCH (TABLE 1)
Yet in 1991, using a hot plate test in a nociceptive pain model, Golombek et al. [5] demonstrated that intraperitoneal injection of 20-40 mg/kg of melatonin produced the strongest analgesic effect if administered in the evening. The analgesic effect decreased after the administration of opiate antagonist naloxone or central benzodiazepine (BZD) antagonist Flumazenil suggesting the involvement of the central opioid and BZD receptors [5] .
In a different study on a nociceptive pain model, Yu et al. [6] demonstrated the dose-dependent effect of melatonin using a group of rats that received intraperitoneal melatonin injections in various doses (30, 60, 120 mg/kg) combined with pain stimulation. The antinociceptive effect took place at 15 min after injection of 60-120 mg/kg of melatonin, peaked at 30 min, and continued for 100 min. The intravenous injection of naloxone neutralized the melatonin analgesic effect in 10 min [6] . Several 
MELATONIN CLINICAL TRIAL EXPERIENCE (TABLE 2)

Melatonin in Migraine
There was much discussion recently that circadian rhythm disorders play an important role in the pathogenesis of headaches. In this situation, melatonin can decrease the frequency and intensity of pain syndromes through inherent analgesic mechanisms and circadian rhythm normalization. Melatonin receptors were found in the ganglia and nuclei of the trigeminal nerve, suggesting that melatonin decreases trigeminal vascular nociception.
Several studies analyzed the association between night melatonin secretion and migraine. The study involving 146 migraine patients revealed a substantially lower urinary level of 6-sulphateoxymelatonin (basic melatonin metabolite) in migraine patients compared to a group of healthy volunteers [12] . Another study involving 34 patients assessed melatonin efficacy in migraine prevention. Peres et al. [13] demonstrated that 3 mg of melatonin before sleep can decrease the frequency, intensity, and duration of pain in migraine patients. In a recent study, the melatonin agonist agomelatine was successfully used in the treatment of migraine patients who took 25 mg/day of agomelatine for 3 months, leading to a decrease in migraine attack frequency and duration. Moreover, agomelatine treatment resulted in depression level decrease and sleep normalization in these patients [14] .
Melatonin in Cluster Headaches
The pathophysiology of cluster headaches remains unclear, but modern concepts suggest the involvement of circadian rhythms in the pathogenesis of this disease; the studies revealed a decrease of night melatonin secretion in the cluster headache patients compared to the healthy controls as well as lower melatonin level during the cluster headache attacks compared to the remission period [15] . In a clinical study, cluster headache patients received 14 days. The study revealed a significant decrease in the intensity and frequency of attacks in the study group compared to the control group. Moreover, the study group showed a tendency towards the decrease of analgesic intake compared to the control group though the difference was insignificant [16] . In a different study, the cluster headache patients took 2 mg of melatonin, however no significant difference in the pain syndrome compared to the control group was found; the findings can be explained by a low melatonin dose [17] .
Melatonin in Tension Headaches
Melatonin demonstrated efficacy in tension headaches. Miano et al. [18] studied the possibility to prevent tension headaches in children. The study involved 21 participants who took 3 g of melatonin before sleep for 3 months. After the therapy, 14 of 21 patients reported a 50% or more decrease in the pain syndrome intensity, and four of them experienced no pain attacks at all [18] .
Melatonin in Chronic Back Pain
The efficacy of melatonin in chronic back pain was then assessed in a study involving 178 patients (aged 40-65 years) with lower back pain over three points measured on a visual analogue scale for at least 12 months. The patients were stratified into six groups making three comparison pairs. The patients in study group 1 (n = 31) took one tablet of Artra conclusion that the addition of melatonin to the standard treatment scheme increases its efficacy in back pain [19] .
Melatonin and Irritable Bowel Syndrome
Besides the epiphysis melatonin is synthesized by enterochromaffin cells in the GIT suggesting melatonin involvement in physiology and pathologies of the GIT. Melatonin synthesis and secretion in the GIT do not follow 24-h cycles. Melatonin stimulates macrophage inhibition and decreases the release of inflammatory mediators, preventing GIT mucosa ulceration and damage to the large intestines. Melatonin can decrease abdominal pains and facilitate defecation, not affecting anxiety and sleep in irritable bowel syndrome patients [20] . On the other hand, there is evidence suggesting the positive impact of melatonin on extra bowel symptoms in irritable bowel syndrome resulting from either anxiolytic or direct effect on the GIT [21] .
Two randomized placebo-controlled clinical trials dealt with melatonin analgesic effects in irritable bowel syndrome patients. In both studies, the patients took 3 mg of melatonin.
One study involved 40 patients who took either placebo or melatonin for 2 weeks [22] . The other study involved 17 patients who took either placebo or melatonin for 8 weeks with a 4-week ''washout'' period [23] . In both of the clinical studies, the patients reported a significant decrease in pain intensity compared to the control groups.
Chojnacki et al. [24] demonstrated that 6-month melatonin administration improves the bowel movement and abdominal pain decrease.
Melatonin in Fibromyalgia
Melatonin secretion disorder may be a part of fibromyalgia pathogenesis. However, the clinical evidence is controversial. Several studies analyzed the circadian rhythms and melatonin secretion in fibromyalgia patients. For example, one study revealed no significant differences in melatonin level in the fibromyalgia patients and in healthy people [25] , while another study found significantly lower urine melatonin concentration in the fibromyalgia patients compared to the healthy controls [26] .
A study was conducted in Russia to investigate the effect of 10-day evening administration of 1. and better fine motor function of the hands in the daytime. The findings suggest melatonin positive effect on the sleep quality in the patients with sleep disorders. These patients also reported a certain decrease of pain and depression levels [27] .
In another open randomized study involving 21 female patients, 3 mg of melatonin was 
Melatonin and Rheumatoid Arthritis
How is melatonin involved in the pathogenesis of rheumatoid arthritis? Compared to healthy people, rheumatoid arthritis patients have a significantly higher level of melatonin secretion at night; in the morning, the blood serum melatonin level is higher in patients with shorter disease history [31, 32] . Inflammation cytokines such as interferon-gamma, interleukin-1, and interleukin-6 are secreted into the peripheral bloodstream in response to melatonin stimulation, moreover, melatonin is found in the synovial liquid in rheumatoid arthritis patients [33] . These findings suggest that melatonin produces an unfavorable influence on rheumatoid arthritis. On the other hand, melatonin inhibits the activity of matrix metalloproteinase (MMP), which is involved in the joint destruction in rheumatoid arthritis patients [34] . Thus, the role of melatonin in joint destruction calls for additional studies. should be kept in mind when selective MT 1 and MT 2 agonists are used [42] .
DISCUSSION OF POSSIBLE ACTION MECHANISMS
As for nuclear receptors, on one hand, RZRb plays a specific role of a transcription factor in the sensory system, and on the other hand, RZRa melatonin receptors are involved in inflammatory reactions. Steinhilber et al. [43] reported that melatonin can decrease the [18] Chronic back pain I a-Artra (combination of 500 mg glucosamine hydrochloride and 500 mg chondroitin sulfate) twice a day for 1 month, then one tablet a day for 2 months and melatonin 3 mg I b-Artra twice a day for 1 month, then one tablet a day for 2 months II a-Artra twice a day, diclofenac 25 mg 2-3 times a day and melatonin 3 mg II b-Artra twice a day, diclofenac 25 mg 2-3 times a day III a-Diclofenac 25 mg 3 times a day and melatonin 3 mg III b-Diclofenac 25 mg 3 times a day It is no doubt that it is too early to consider melatonin as an analgesic. Nevertheless, given melatonin's potential in relation to both neuropathic and nociceptive pain, melatonin deserves special attention and may become an efficient addition to the existing drugs for pain syndrome treatment.
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